Open AccessPreventive effects of statins on the incidence of liver cancer
Author(s) -
Hamid Salehiniya,
Khadijah Allah Bakeshei,
Abdollah Mohammadian-Hafshejani
Publication year - 2018
Publication title -
biomedical research and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 1
ISSN - 2198-4093
DOI - 10.15419/bmrat.v5i3.426
Subject(s) - medicine , cancer , statin , disease , liver cancer , stroke (engine) , case fatality rate , incidence (geometry) , randomized controlled trial , epidemiology , mechanical engineering , physics , optics , engineering
Liver cancer is considered as one of the most common cancers in the world, so that it is ranked fifth in males and sixth in females in the world causing high annual costs to patients, the health system and society (Ferlay et al., 2015). The worldwide mortality rate of this disease is rising annually. This disease also has a very high fatality, so that 88% of patients in USA (Miller et al., 2016) and 90% of patients in China (Zeng et al., 2015) die of this disease in the first 5 years of its diagnosis. Therefore, it is essential to identify factors which protect against this disease. The protective effects of Statins against the cardiovascular diseases, stroke and heart attack has been proven (Tobert, 1996). Recent studies have found that Statins can also have protective effects against the cancers (Yi, Song, Wan, Chen, & Cheng, 2017). Several meta-analysis studies have explored the relationship between Statin receiving and the risk of developing liver cancer by application of randomized clinical trials, and found that the use of Statins significantly reduces the risk of liver cancer.